Treatment-related adverse events, immune-related adverse events and discontinuation in patients with solid tumors adding adjuvant immune checkpoint blockade: a meta-analysis of 38 randomized controlled trials
{{output}}
Background: The safety profile of immune checkpoint blockade (ICB) in the adjuvant setting has not been well characterized. This study aims to summarize the incidences of adverse events (AEs) in patients with solid tumors receivi... ...
